Psychopharmacology

, Volume 183, Issue 2, pp 257–264 | Cite as

Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test

Original Investigation

Abstract

Rationale

Variations in the effects of antidepressant drugs between different mouse strains are important for drug discovery and could lead to the identification of genes that predict differences in drug efficacy.

Objectives

This study compared behavioral baselines and dose-dependent responses to the selective serotonin reuptake inhibitor (SSRI) citalopram in eight inbred mouse strains (C57BL/6J, DBA/2J, C3H/HeJ, BALB/cJ, A/J, 129/SvEmsJ, 129/SvImJ, and BTBR) using the tail suspension test (TST).

Results

The DBA/2J, BALB/cJ, and BTBR strains were the most responsive to the effects of citalopram. Citalopram was least effective in the C57BL/6J and A/J strains. The antidepressant-like effects of citalopram in the TST were not correlated with changes in locomotor activity or deprivation-induced feeding behavior across the individual mouse strains, suggesting that patterns of sensitivity to citalopram are behaviorally specific and unlikely to result from pharmacokinetic variables. As an initial search for genetic polymorphisms causing differences in citalopram sensitivity, polymorphic forms of the tryptophan hydroxylase 2 (tph2) gene were genotyped and found to be not correlated with citalopram responsive (DBA/2J and BALB/cJ) and nonresponsive (A/J and C57BL/6J) strains.

Conclusions

The TST strain survey described here: (1) suggested the most appropriate strains for screening potential antidepressants, (2) identified parental strains appropriate for quantitative trait loci mapping of genomic loci regulating SSRI sensitivity, and (3) indicated appropriate background strains for measuring an antidepressant-like response to the SSRI citalopram. The pattern of response agrees with a previous mouse strain survey that examined sensitivity to fluoxetine in the forced swim test (Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155:315–322).

Keywords

Tail suspension test Depression Citalopram Genetics Pharmacogenetics Mouse 

References

  1. Arias B, Catalan R, Gasto C, Imaz ML, Gutierrez B, Pintor L et al (2001) Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long-term treatment with citalopram. World J Biol Psychiatry 2:9SCrossRefGoogle Scholar
  2. Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ (2002) Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav 71:667–680CrossRefPubMedGoogle Scholar
  3. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389CrossRefPubMedGoogle Scholar
  4. Crowley JJ, Lucki I (2005) Opportunities to discover genes regulating depression and antidepressant response from rodent behavioral genetics. Curr Pharm Des 11:157–169CrossRefPubMedGoogle Scholar
  5. Crowley JJ, Jones MD, O'Leary OF, Lucki I (2004) Automated tests for measuring the effects of antidepressants in mice. Pharmacol Biochem Behav 78:269–274CrossRefPubMedGoogle Scholar
  6. Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev in pressGoogle Scholar
  7. David DJP, Renard CE, Jolliet P, Hascoet M, Bourin M (2003) Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology 166:373–382PubMedGoogle Scholar
  8. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB (2004) The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology 174:525–529CrossRefPubMedGoogle Scholar
  9. Edenberg HJ, Foroud T, Conneally PM, Sorbel JJ, Carr K, Crose C et al (1997) Initial genomic scan of the NIMH genetics initiative bipolar pedigrees: chromosomes 3, 5, 15, 16, 17, and 22. Am J Med Genet 74:238–246CrossRefPubMedGoogle Scholar
  10. Hyttel J (1993) Comparative pharmacology of selective serotonin reuptake inhibitors. Nord J Psychiatry 47(Suppl 30):5–20CrossRefGoogle Scholar
  11. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al (2000) Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11:215–219PubMedCrossRefGoogle Scholar
  12. Kremer I, Bachner-Melman R, Reshef A, Broude L, Nemanov L, Gritsenko I, Heresco-Levy U, Elizur Y, Ebstein RP (2005) Association of the serotonin transporter gene with smoking behavior. Am J Psychiatry 162:924–930CrossRefGoogle Scholar
  13. Lander ES, Botstein D (1989) Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 121:185–199PubMedGoogle Scholar
  14. Liu X, Gershenfeld HK (2001) Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biol Psychiatry 49:575–581CrossRefPubMedGoogle Scholar
  15. Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155:315–322CrossRefPubMedGoogle Scholar
  16. Mayorga AJ, Lucki I (2001) Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacology 155:110–112CrossRefPubMedGoogle Scholar
  17. Nelson JC (1999) A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 46:1301–1308CrossRefPubMedGoogle Scholar
  18. Perrault GH, Morel E, Zivkovic B, Sanger DJ (1992) Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice. Pharmacol Biochem Behav 42:45–47CrossRefPubMedGoogle Scholar
  19. Pollack BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al (2000) Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587–590CrossRefPubMedGoogle Scholar
  20. Ripoll N, David DJ, Dailly E, Hascoet M, Bourin M (2003) Antidepressant-like effects in various mice strains in the tail suspension test. Behav Brain Res 3633:1–8Google Scholar
  21. Schinka JA, Busch RM, Robichaux-Keene N (2004) A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 9:197–202CrossRefPubMedGoogle Scholar
  22. Serretti A, Lilli R, Smeraldi E (2002) Pharmacogenetics in affective disorders. Eur J Pharmacol 438:117–128PubMedCrossRefGoogle Scholar
  23. Shanks N, Anisman H (1989) Strain-specific effects of antidepressants on escape deficits induced by inescapable shock. Psychopharmacology 99:122–128CrossRefPubMedGoogle Scholar
  24. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508–511CrossRefPubMedGoogle Scholar
  25. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367–370CrossRefPubMedGoogle Scholar
  26. Wehner JM, Radcliffe RA, Bowers BJ (2001) Quantitative genetics and mouse behavior. Annu Rev Neurosci 24:845–867CrossRefPubMedGoogle Scholar
  27. Yamada K, Watanabe A, Iwayama-Shigeno Y, Yoshikawa T (2003) Evidence of association between gamma-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders. Neurosci Lett 349:9–12CrossRefPubMedGoogle Scholar
  28. Yoshikawa T, Watanabe A, Ishitsuka Y, Nakaya A, Nakatani N (2002) Identification of multiple genetic loci linked to the propensity for “behavioral despair” in mice. Genome Res 12:357–366CrossRefPubMedGoogle Scholar
  29. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000) Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20:105–107CrossRefPubMedGoogle Scholar
  30. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E et al (2001) Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50:323–330CrossRefPubMedGoogle Scholar
  31. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG (2004) Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 305:217PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • James J. Crowley
    • 1
  • Julie A. Blendy
    • 1
  • Irwin Lucki
    • 1
    • 2
  1. 1.Department of PharmacologyUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations